Trichohyalin Inhibitors
Trichohyalin inhibitors comprise a diverse class of chemical compounds designed to modulate the activity of Trichohyalin, a protein associated with skin development, wound healing, and tissue homeostasis. While there are no direct inhibitors identified, several chemicals targeting the TGF-β signaling pathway can influence Trichohyalin-related pathways. SB-431542 and LY-364947 are selective inhibitors of the TGF-β receptor kinase, providing a means to indirectly impact Trichohyalin by interfering with TGF-β signaling. These small molecules may disrupt the downstream pathways regulated by TGF-β, affecting the expression or function of Trichohyalin and influencing cellular processes associated with skin development and homeostasis. Pirfenidone, Galunisertib, RepSox, and LY2157299 are compounds known for their effects on TGF-β signaling. By targeting TGF-β receptor kinases, these inhibitors can indirectly modulate Trichohyalin-related pathways, offering insights into cellular processes involved in skin integrity, wound healing, and tissue repair.
Fresolimumab, a TGF-β neutralizing antibody, and SD-208, a TGF-β receptor kinase inhibitor, provide targeted approaches to disrupt TGF-β-mediated pathways, impacting Trichohyalin expression or activity and influencing cellular processes associated with skin development and tissue homeostasis. A83-01, TGF-β1 Inhibitor IV, EW-7197, and Reparixin offer additional TGF-β receptor kinase inhibitors with implications for Trichohyalin regulation. These compounds selectively target the TGF-β signaling pathway, providing a nuanced toolkit to explore the intricate regulatory roles of Trichohyalin in skin biology. In summary, Trichohyalin inhibitors represent a valuable set of compounds for researchers aiming to decipher the specific functions of Trichohyalin in various cellular processes. These chemicals, through their selective modulation of TGF-β signaling, can indirectly impact Trichohyalin-related pathways, shedding light on the protein's roles in skin development, wound healing, and tissue homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 is a selective inhibitor of the TGF-β receptor kinase, potentially modulating signaling pathways involved in Trichohyalin regulation. By interfering with TGF-β signaling, it can indirectly influence the expression or activity of Trichohyalin, impacting cellular processes related to skin development and homeostasis. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $107.00 $156.00 | 4 | |
LY-364947 is a small molecule inhibitor that targets the TGF-β receptor kinase, offering a potential means to modulate Trichohyalin-related pathways. By inhibiting TGF-β signaling, this compound can indirectly impact Trichohyalin expression or activity, affecting cellular processes associated with skin development and maintenance. | ||||||
Pirfenidone | 53179-13-8 | sc-203663 sc-203663A | 10 mg 50 mg | $102.00 $416.00 | 6 | |
Pirfenidone is an anti-fibrotic drug known for its inhibitory effects on TGF-β signaling. By targeting TGF-β, Pirfenidone may indirectly influence Trichohyalin regulation, impacting cellular processes related to skin integrity and homeostasis. The compound is recognized for its potential to modulate TGF-β-mediated pathways, which can have downstream effects on Trichohyalin. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $213.00 $359.00 | 3 | |
Galunisertib (LY2157299) is a TGF-β receptor kinase inhibitor that can potentially modulate Trichohyalin-related pathways by interfering with TGF-β signaling. Its selective action on the TGF-β pathway may indirectly impact the expression or function of Trichohyalin, affecting cellular processes associated with skin development, wound healing, and tissue homeostasis. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $77.00 $153.00 $219.00 $663.00 $1248.00 $4382.00 $7850.00 | 8 | |
RepSox (ALK5 Inhibitor II) is a small molecule inhibitor targeting TGF-β receptor kinases, providing a potential avenue for influencing Trichohyalin-related pathways. By inhibiting TGF-β signaling, RepSox may indirectly modulate the expression or activity of Trichohyalin, impacting cellular processes involved in skin development and maintenance, as well as potential roles in wound healing and tissue repair. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $88.00 | 3 | |
TGF-β RI Kinase Inhibitor V (SD-208) is a TGF-β receptor kinase inhibitor that may provide a means to indirectly modulate Trichohyalin-related pathways. By inhibiting TGF-β signaling, SD-208 can potentially influence the expression or activity of Trichohyalin, impacting cellular processes associated with skin development, wound healing, and tissue homeostasis. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A83-01 is a TGF-β receptor kinase inhibitor with potential implications for Trichohyalin regulation. By targeting the TGF-β signaling pathway, A83-01 may indirectly influence the expression or activity of Trichohyalin, impacting cellular processes associated with skin development, wound healing, and tissue homeostasis. The compound offers a selective approach to modulate TGF-β-mediated pathways. | ||||||
EW-7197 | 1352608-82-2 | sc-507465 | 5 mg | $345.00 | ||
EW-7197 is a TGF-β receptor kinase inhibitor that may offer a means to indirectly modulate Trichohyalin-related pathways. By targeting TGF-β signaling, EW-7197 can potentially influence the expression or activity of Trichohyalin, impacting cellular processes associated with skin development, wound healing, and tissue homeostasis. The compound provides a selective approach to disrupt TGF-β-mediated pathways. | ||||||
Reparixin | 266359-83-5 | sc-507446 | 5 mg | $78.00 | ||
Reparixin is a CXCR1/2 antagonist with potential implications for Trichohyalin-related pathways. By targeting the chemokine receptor CXCR1/2, Reparixin may indirectly modulate Trichohyalin expression or activity, impacting cellular processes associated with skin development, inflammation, and tissue homeostasis. The compound offers a selective approach to disrupt specific signaling cascades linked to Trichohyalin regulation. | ||||||